Phase 1/2 study of BLU-451, a small molecule inhibitor of EGFR, in EGFR exon 20 insertion-mutant incurable advanced cancers Meeting Abstract
| Authors: | Spira, A.; Yu, H.; Sun, L.; Nguyen, D.; Parepally, J.; Albayya, F.; Patel, S.; Zhang, H.; Zalutskaya, A.; Le, X. |
| Abstract Title: | Phase 1/2 study of BLU-451, a small molecule inhibitor of EGFR, in EGFR exon 20 insertion-mutant incurable advanced cancers |
| Meeting Title: | 2022 World Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 17 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2022 Aug 6-9 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S405 |
| End Page: | S406 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.07.700 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: EP08.02-018 -- Located within section named "EP08.02 Metastatic Non-Small Cell Lung Cancer - Molecular Targeted Treatments" -- Accession Number: 159037946 -- Entry Date: In Process -- Revision Date: 20220913 -- Publication Type: Article -- Supplement Title: 2022 Supplement -- Journal Subset: Biomedical; Blind Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101274235. -- Source: Cinahl |
